# A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Source: https://onco.cc/trials/nct06051409/  
OnCo record `nct06051409` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.

## Summary

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) is a phase 3 interventional study registered as NCT06051409 by Ascentage Pharma Group Inc., with 350 participants planned, started 2023-08-31. Conditions listed: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06051409
- Phase: 3
- Setting: A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT06051409: https://clinicaltrials.gov/study/NCT06051409

## Connected records

- drugs: [Olverembatinib](https://onco.cc/drugs/olverembatinib/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06051409.json